Literature DB >> 2546328

Intranasal immunization with proteoliposomes protects against influenza.

N el Guink1, R M Kris, G Goodman-Snitkoff, P A Small, R J Mannino.   

Abstract

Worldwide, influenza virus remains a serious disease which has successfully eluded numerous attempts to design a consistently effective vaccine. In part, these attempts have been thwarted because of a lack of basic understanding of the mechanisms which mediate protection and recovery from influenza infection. A better understanding of the roles of secretory antibody, serum antibody and cell mediated immunity vis-à-vis protection and recovery from influenza infection has allowed us more rationally to approach the design and administration of a vaccine for influenza. We have constructed a vaccine composed of glycoproteins from the envelopes of either influenza of Sendai virus embedded in a lipid bilayer (immunosomes) mimicking the presentation of the virus to the cells during natural infection. Intranasal immunization with these immunosomes induces an adequate systemic Ir compared with intramuscular immunization and a superior local IgA response. These animals were specifically protected from virus challenge.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2546328     DOI: 10.1016/0264-410x(89)90055-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen.

Authors:  N K Childers; K L Miller; G Tong; J C Llarena; T Greenway; J T Ulrich; S M Michalek
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responses.

Authors:  N K Childers; G Tong; S Mitchell; K Kirk; M W Russell; S M Michalek
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

Review 3.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

4.  Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines.

Authors:  G H Lowell; C Colleton; D Frost; R W Kaminski; M Hughes; J Hatch; C Hooper; J Estep; L Pitt; M Topper; R E Hunt; W Baker; W B Baze
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

Review 5.  Is there a role for a mucosal influenza vaccine in the elderly?

Authors:  E M Corrigan; R L Clancy
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

Review 6.  Mucosal vaccines for the prevention of influenza.

Authors:  R L Clancy
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 7.  Cellular immunity and memory to respiratory virus infections.

Authors:  D L Woodland; R J Hogan; W Zhong
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

8.  Influence of intravenous anesthesia on mucosal and systemic antibody responses to nasal vaccines.

Authors:  Libuse Janakova; Hilde Bakke; Inger Lise Haugen; Aud K H Berstad; E Arne Høiby; Ingeborg S Aaberge; Bjørn Haneberg
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

Review 9.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

10.  A potential peptide vaccine against two different strains of influenza virus isolated at intervals of about 10 years.

Authors:  H Naruse; K Ogasawara; R Kaneda; S Hatakeyama; T Itoh; H Kida; T Miyazaki; R A Good; K Onoé
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.